ArticleCancer medicine2016
Gastrointestinal follicular lymphoma: using primary site as a predictor of survival.
Article in Cancer medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Follicular Lymphoma Arising in an Ileal Neobladder Presenting as a Large Pelvic Mass.IJU case reports · 2026Article
- Beyond the Surface: Duodenal-Type Follicular Lymphoma Diagnosed Despite Normal-Appearing Duodenal Mucosa and Absence of Focal Duodenal FDG Uptake.Case reports in gastrointestinal medicine · 2026Article
- Two Cases of Small Intestinal Follicular Lymphoma Presenting with Intestinal Stricture.Surgical case reports · 2025Article
- The association between radiotherapy and the prognosis of follicular lymphoma patients with different characteristics in the rituximab era: a cohort study based on Surveillance, Epidemiology and End Results.Annals of hematology · 2025Article
- Incidental Finding of a Duodenal-Type Follicular Lymphoma in Metabolic Dysfunction-Associated Steatohepatitis Cirrhosis: A Rare Malignancy With Favorable Outcomes.ACG case reports journal · 2024Article
- Multifocal Follicular Lymphoma Isolated to the Gastrointestinal Tract: A Rare Finding.ACG case reports journal · 2023Article
- Common Presentation of an Uncommon Small Intestinal Lymphoma: A Rare Case Entity.Gastrointestinal tumors · 2021Article
- Surgical Management of Small Bowel Lymphoma.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2021Article
- Changes in Incidence and Survival by Decade of Patients With Primary Colorectal Lymphoma: A SEER Analysis.Frontiers in public health · 2020Article
- Primary duodenal follicular lymphoma with late disseminated nodal relapse responsive to rituximab monotherapy: A case report.Molecular and clinical oncology · 2017Article
- Gastrointestinal follicular lymphoma: using primary site as a predictor of survival.Cancer medicine · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastrointestinal follicular lymphoma (GI-FL) is a rare extranodal variant of follicular lymphoma (FL) that has been increasingly reported in the literature. An especially indolent course is linked to the disease after a lack of observed patient death in past studies. However, overall survival (OS) and associated prognostic factors remain unclear. A large population-based database was utilized to identify demographic and clinicopathologic characteristics of GI-FL, along with survival differences among primary sites. The Surveillance, Epidemiology, and End Results Registry was used to identify GI-FL cases between the years of 1973 and 2012. Kaplan-Meier curves compared OS differences and Cox proportional hazard models analyzed prognostic factors. Final analysis included 1109 cases. Small intestinal cases, which included those with single-site and multi-segment involvement, were most common (63.6%) followed by gastric (18.2%) and colorectal cases (18.2%). Small intestinal GI-FL presented more frequently with grade I histology, and less often with grade III histology (P < 0.001 and P < 0.001, respectively). Small intestinal cases had better outcomes (5-year OS = 80.9%, P < 0.001) compared to cases involving the stomach (5-year OS = 52.7%) and colorectum (5-year OS = 71.5%). On multivariate analysis for predictors of mortality, small intestinal involvement predicted for better survival; hazard ratio (HR) 0.66 (95% CI: 0.51-0.85). Advanced age (≥66), grade (grade III), and stage (Ann Arbor Stage III/IV) predicted for mortality with HR 5.46 (95% CI: 3.80-7.84), 1.42 (95% CI: 1.10-1.83), 1.57 (95% CI: 1.15-2.16), respectively. GI-FL has poorer outcomes than previously suggested. Small intestinal involvement has a better prognosis. A possible biological basis for this will require further investigations in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.